Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AETHER: venetoclax with 6 vs 12 cycles of epcoritamab in relapsed or refractory CLL/SLL
2022-500305-40-00Phase 2Authorised
- Sponsor
- HOVON
- Start
- Jan 2024
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of venetoclax and epcoritamab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by HOVON. Primary endpoints: Recommended phase II dose and Bone marrow uMRD4 at post-treatment assessment. Planned start Jan 2024; status: authorised.
02
Drugs
venetoclaxepcoritamab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2022-500305-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500305-40-00.